Cryptococcosis screening: Difference between revisions
Jump to navigation
Jump to search
Created page with "__NOTOC__ {{Cryptococcosis}} Please help WikiDoc by adding content here. It's easy! Click here to learn about editing. ==References== {{Refl..." |
Sergekorjian (talk | contribs) No edit summary |
||
| Line 2: | Line 2: | ||
{{Cryptococcosis}} | {{Cryptococcosis}} | ||
==Overview== | |||
==Screening== | |||
*Early studies demonstrated that asymptomatic cryptococcal antigenemia can be detected in up to 12% of patients with HIV/AIDS in endemic regions. | |||
*Cryptococcus neoformans was also demonstrated by direct microscopy and culture in the cerebrospinal fluid of approximately 2/3 of patients. | |||
*Further studies conducted in endemic regions in Africa (South Africa, Uganda) demonstrated that asymptomatic cryptococcal antigenemia ranged from 7 to 38%. | |||
*Asymptomatic antigenemia was also demonstrated to be an independent predictor of mortality among these patients, and, during the first year of ART, an antigen titer greater than 1:8 was 100% sensitive and 96% specific for predicting the incidence of cryptococcal meningitis. | |||
*These alarming findings raised a question about the possibility of developing screening programs among high risk HIV/AIDS patients, and providing patients with fluconazole prophylaxis the decrease the risk of active infections. | |||
*Concerns about the cost effectiveness and efficacy of screening and subsequent prophylaxis have not been addressed in adequately designed and powered studies. | |||
*The limited body of evidence suggests that screening and treatment reduces the incidence of cryptococcal meningitis and death in persons with AIDS.<ref name="pmid25768872">{{cite journal| author=Kaplan JE, Vallabhaneni S, Smith RM, Chideya-Chihota S, Chehab J, Park B| title=Cryptococcal antigen screening and early antifungal treatment to prevent cryptococcal meningitis: a review of the literature. | journal=J Acquir Immune Defic Syndr | year= 2015 | volume= 68 Suppl 3 | issue= | pages= S331-9 | pmid=25768872 | doi=10.1097/QAI.0000000000000484 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25768872 }} </ref> | |||
===Methods of Screening=== | |||
*The majority of studies on cryptococcal screening have used cryptococcal antigen also know as CrAg.<ref name="pmid25768872">{{cite journal| author=Kaplan JE, Vallabhaneni S, Smith RM, Chideya-Chihota S, Chehab J, Park B| title=Cryptococcal antigen screening and early antifungal treatment to prevent cryptococcal meningitis: a review of the literature. | journal=J Acquir Immune Defic Syndr | year= 2015 | volume= 68 Suppl 3 | issue= | pages= S331-9 | pmid=25768872 | doi=10.1097/QAI.0000000000000484 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25768872 }} </ref> | |||
*New point-of-care methods for detecting CrAg have been developed. | |||
*A dipstick test that requires a small blood sample can detect silent antigenemia with high sensitivity in less than 10 minutes and for a small cost (less than $2) has been introduced in 2014.<ref name=cdc>Preventing Deaths Due to Cryptococcus with Targeted Screening. Centers for Disease Control and Prevention (2015). http://www.cdc.gov/fungal/diseases/cryptococcosis-neoformans/screening.html. Accessed on December 20, 2015</ref><ref name="pmid24065327">{{cite journal| author=Kabanda T, Siedner MJ, Klausner JD, Muzoora C, Boulware DR| title=Point-of-care diagnosis and prognostication of cryptococcal meningitis with the cryptococcal antigen lateral flow assay on cerebrospinal fluid. | journal=Clin Infect Dis | year= 2014 | volume= 58 | issue= 1 | pages= 113-6 | pmid=24065327 | doi=10.1093/cid/cit641 | pmc=PMC3864499 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24065327 }} </ref> | |||
===Recommendations=== | |||
*Given that the efficacy of such an approach has not been thoroughly studied, the IDSA does not recommend routine screening for asymptomatic antigenemia in HIV-infected patients in the United States and Europe. | |||
*However, the IDSA recommends that areas with limited HAART availability, high levels of antiretroviral drug resistance, and a high burden of disease should consider it. | |||
*In the case of asymptomatic antigenemia, a lumbar puncture and a blood culture are recommended. | |||
*Positive results should warrant treatment as symptomatic meningoencephalitis and/or disseminated disease if any signs/symptoms are present. | |||
*However, without evidence of meningoencephalitis, patients should be treated with fluconazole 400 mg PO qd. | |||
Click [[Cryptococcosis medical therapy|here]] to learn more about the regimens used for the treatment of symptomatic meningoencephalitis and/or disseminated disease. | |||
==References== | ==References== | ||
Revision as of 17:35, 20 January 2016
|
Cryptococcosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Cryptococcosis screening On the Web |
|
American Roentgen Ray Society Images of Cryptococcosis screening |
|
Risk calculators and risk factors for Cryptococcosis screening |
Overview
Screening
- Early studies demonstrated that asymptomatic cryptococcal antigenemia can be detected in up to 12% of patients with HIV/AIDS in endemic regions.
- Cryptococcus neoformans was also demonstrated by direct microscopy and culture in the cerebrospinal fluid of approximately 2/3 of patients.
- Further studies conducted in endemic regions in Africa (South Africa, Uganda) demonstrated that asymptomatic cryptococcal antigenemia ranged from 7 to 38%.
- Asymptomatic antigenemia was also demonstrated to be an independent predictor of mortality among these patients, and, during the first year of ART, an antigen titer greater than 1:8 was 100% sensitive and 96% specific for predicting the incidence of cryptococcal meningitis.
- These alarming findings raised a question about the possibility of developing screening programs among high risk HIV/AIDS patients, and providing patients with fluconazole prophylaxis the decrease the risk of active infections.
- Concerns about the cost effectiveness and efficacy of screening and subsequent prophylaxis have not been addressed in adequately designed and powered studies.
- The limited body of evidence suggests that screening and treatment reduces the incidence of cryptococcal meningitis and death in persons with AIDS.[1]
Methods of Screening
- The majority of studies on cryptococcal screening have used cryptococcal antigen also know as CrAg.[1]
- New point-of-care methods for detecting CrAg have been developed.
- A dipstick test that requires a small blood sample can detect silent antigenemia with high sensitivity in less than 10 minutes and for a small cost (less than $2) has been introduced in 2014.[2][3]
Recommendations
- Given that the efficacy of such an approach has not been thoroughly studied, the IDSA does not recommend routine screening for asymptomatic antigenemia in HIV-infected patients in the United States and Europe.
- However, the IDSA recommends that areas with limited HAART availability, high levels of antiretroviral drug resistance, and a high burden of disease should consider it.
- In the case of asymptomatic antigenemia, a lumbar puncture and a blood culture are recommended.
- Positive results should warrant treatment as symptomatic meningoencephalitis and/or disseminated disease if any signs/symptoms are present.
- However, without evidence of meningoencephalitis, patients should be treated with fluconazole 400 mg PO qd.
Click here to learn more about the regimens used for the treatment of symptomatic meningoencephalitis and/or disseminated disease.
References
- ↑ 1.0 1.1 Kaplan JE, Vallabhaneni S, Smith RM, Chideya-Chihota S, Chehab J, Park B (2015). "Cryptococcal antigen screening and early antifungal treatment to prevent cryptococcal meningitis: a review of the literature". J Acquir Immune Defic Syndr. 68 Suppl 3: S331–9. doi:10.1097/QAI.0000000000000484. PMID 25768872.
- ↑ Preventing Deaths Due to Cryptococcus with Targeted Screening. Centers for Disease Control and Prevention (2015). http://www.cdc.gov/fungal/diseases/cryptococcosis-neoformans/screening.html. Accessed on December 20, 2015
- ↑ Kabanda T, Siedner MJ, Klausner JD, Muzoora C, Boulware DR (2014). "Point-of-care diagnosis and prognostication of cryptococcal meningitis with the cryptococcal antigen lateral flow assay on cerebrospinal fluid". Clin Infect Dis. 58 (1): 113–6. doi:10.1093/cid/cit641. PMC 3864499. PMID 24065327.